For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
We advise on real world evidence (RWE) strategies throughout the product lifecycle to inform clinical development, reduce risk, improve the patient experience, and fulfill requirements from regulators and payers.
Real world evidence in clinical trials can answer key questions and promote a better understanding of patient experiences and outcomes. A foundation built from RWE supports the delivery of therapies that more closely match patient needs.
Effectively meeting the needs of multiple stakeholders (regulators, payers, physicians, and patients) takes a diverse bench of expertise. At Parexel, you have access to the best in access consulting, regulatory affairs, clinical research, medical affairs, health economics and outcomes research (HEOR), pricing and reimbursement, epidemiology, biostatistics, we effectively meet the needs of multiple stakeholders (regulators, payers, physicians, and patients). We help you build a value story early in development by crafting a fit-for-purpose strategy designed to support your product position in the context of:
With our proprietary cloud-based infrastructure, we’re capable of linking large volumes of data and applying sophisticated analytics and data visualization to identify evidence gaps and patient experience insights. We can also migrate data to your technologies, ensuring valid, accurate, and strategically derived assets.
By examining the ways drugs work in large populations, we’re better able to understand disease conditions, patient experience and the impact of therapies in large populations. Our specialists in epidemiology and biostatistics help you choose the right methodology depending on your specific objectives, using a variety of tools for this purpose, including:
Models generated from health claims, EMRs and other RWE sources
Our cross-functional teams, established processes, and cloud-based technology platform generate fit-for-purpose real-world data that strategically supports scientific or commercial analysis.
Observational research offers broad ways to answer questions about product performance, long-term safety, and patient outcomes. Non-interventional studies can help you understand more about causal associations between treatments and outcomes, and about the disease conditions in general.
Our team of pharmacoepidemiologists and pharmacovigilance, regulatory, and research operations advisors can do the following:
We provide multiple options for late-stage programs, based on safety commitments, product strategy and additional data needs for regulators and payers, with experience in peri/post-approval research to back it up.
We offer strategic and scientific guidance on design, implementation, and dissemination of patient-centric data generation throughout the product development lifecycle, with end-to-end reporting. As experts in the strategic application of PRO data as proof of outcomes and value and to fill evidence gaps, we handle licensing, translations, normative data, and migration to electronic PRO (ePRO).
FREQUENTLY ASKED QUESTIONS
RWE describes clinical evidence about the usage and potential benefits or risks of a medical product or practice. RWE is derived from the transformation, analysis, and interpretation of real-world data (RWD) for use in clinical, policy, payer, or other decisions.
RWE drives the differentiation of value against standard of care, comparable products on the market and new entrants.
Early in the clinical trial planning process, RWE helps identify the appropriate patient populations, and utilizes RWD sources to support inclusion/exclusion criteria.
RWE empowers innovative trials. By combining site-based data with electronic health records and registry data, phase II/III hybrid trials can be conducted. RWE also enhances data from single-arm trials by utilizing external/historic controls. Furthermore, it allows for the creation of external control arms to validate more rigorous comparison to patients in active treatment arms.
RWE is useful for drug approval because it allows for informed decision making at the right time and assists companies in meeting the expectations of regulators. By utilizing RWD, it enhances the pathway to regulatory approval, from integrated product development planning, through health authority engagement to regulatory submission. And it demonstrates value through evidence-based health economic evaluation and outcomes research.
Parexel Recognized with Frost & Sullivan's 2023 North American Customer Value Leadership Award for impactful real-world evidence solutions addressing customer needs.